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and longer DAPT (L-DAPT) deﬁned as the per-protocol period of
prolonged DAPT beyond S-DAPT. The primary outcome was the
study-deﬁned major adverse cardiac events (MACE). Random effect
models were used as primary analytic approach with generic in-
verse variance using effect estimates and standard errors extracted
from each RCT’s gender subgroup analysis. Heterogeneity was
assessed with I2 test (with I2 > 75% indicating substantial hetero-
geneity). Analyses were conducted with Cochrane’s Review Man-
ager (RevMan) version 5.3.
RESULTS A total of 13 RCTs with 108.069 patients have been
included in the ﬁnal dataset. Of them, 31,390 (29%) were women
and 76,679 (71%) were men. Mean weighted exposure time to DAPT
was 2.4 months and 5.9 months in the S-DAPT and L-DAPT groups
respectively. Compared with S-DAPT, L-DAPT was associated with a
signiﬁcant reduction in MACE in the overall cohort (Figure. HR:
0.87; 95% CI: 0.82 – 0.92; p < 0.00001; I2 ¼ 18%). However, the
beneﬁt of L-DAPT was accentuated in men (HR: 0.82; 95% CI:
0.76 – 0.90; p < 0.00001) as compared to women (HR: 0.93; 95%
CI: 0.86 – 1.00; p ¼ 0.06) with evidence of statistical interaction
(p for interaction ¼ 0.03).CONCLUSIONS According to the results of the present study-level
metanalysis, the beneﬁts of DAPT appear to be less in women as
compared to men, a ﬁnding that warrants prospective conﬁrmation.
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BACKGROUND Longer DAPT (> 12 months) after drug-eluting stent
(DES) implantation is associated with a lower risk of myocardial
infarction (MI) counterbalanced by a higher risk of major bleeding
events. We sought to simulate the therapeutic risks and beneﬁts of
longer versus short DAPT durations after PCI using evidence from
randomized controlled trials (RCT).
METHODS Using frequentist meta-analytic techniques, we calculated
summary effect estimates for both MI and clinically signiﬁcant
bleeding (CSB) associated with longer (L-DAPT) versus shorter (S-
DAPT) DAPT durations based on results of 10 RCT (n¼32,135). We then
calculated the number needed to treat (NNT) and number needed toharm (NNH) as a function of baseline thrombotic and bleeding risk.
NNT/NNH ratios > 1 were considered as evidence of therapeutic harm
while ratios < 1 were classiﬁed as beneﬁcial.
RESULTS The mean weighted follow-up time among all trials was
19.6 months. Mean weighted exposure time to DAPT was 23.2
months and 8.5 months in L-DAPT and S-DAPT groups respectively.
As compared to S-DAPT, L-DAPT was associated with a lower risk of
MI (odds ratio [OR]: 0.72; 95% CI: 0.62 – 0.83; p < 0.0001).
Conversely, L-DAPT was associated with a higher risk of CSB (OR:
1.59; 95% CI: 1.31 – 1.92; p < 0.00001). The net clinical beneﬁt in the
trade-off between ST and CSB across a range of bleeding and
ischemic risk scenarios is illustrated in Figure 1. With L-DAPT, the
beneﬁt on MI outweighed the risk for bleeding with a ST risk > 6%
and a CSB risk  3%.
CONCLUSIONS Our results suggest that the beneﬁts of longer DAPT
durations may be optimal in patients at high thrombotic or low
bleeding risk, ﬁndings that warrant prospective evaluation.CATEGORIES CORONARY: Pharmacology/Pharmacotherapy
KEYWORDS Bleeding, Dual antiplatelet therapy, ThrombosisTCT-219
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BACKGROUND Randomized data have shown that prasugrel is supe-
rior to clopidogrel in reducing ischemic risk including unplanned
revascularization, albeit with increased bleeding. Greater stent length
is also an independent correlate of adverse events after percutaneous
coronary intervention (PCI). We sought to determine whether
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5 B85prasugrel inﬂuences ischemic beneﬁt in real world acute coronary
syndrome (ACS) patients irrespective of stent length.
METHODS PROMETHEUS was a retrospective multicenter observa-
tional study comparing clopidogrel and prasugrel use in patients un-
dergoing PCI for acute coronary syndrome. MACE was deﬁned as a
composite of death, myocardial infarction, stroke and unplanned
revascularization at one year. We compared outcomes between clo-
pidogrel and prasugrel treatment stratiﬁed by stent length < or 40
mm.
RESULTS Prasugrel was given to 20.0% and 22.0% of patients
receiving short (n¼14790) and long stents (n¼4695) respectively.
Compared with clopidogrel treated patients, those receiving prasugrel
were younger, more often male, with lower frequencies of diabetes,
prior PCI, renal dysfunction and anemia but higher left ventricular
ejection fraction. The incidence of STEMI presentation, B2/C type
lesions, single vessel and non-signiﬁcantly calciﬁed disease was
higher in prasugrel treated patients with a greater likelihood to
receive drug eluting stents and stents >2.5mm in diameter. The
overall crude MACE rate for the study population was 12.1% vs 20.7%
with prasugrel compared with clopidogrel, p<0.001. In the short-
stent group prasugrel was associated with a signiﬁcantly lower risk
for MACE prior to adjustment (10.7% vs. 18.6%, p<0.001). Analogous
event rates in the long-stent group were 15.8% and 26.7%, respec-
tively (p<0.001). Results remained signiﬁcant for short but not long
stents after adjustment without evidence of interaction (p¼0.98)
(Figure).
CONCLUSIONS Compared with clopidogrel, prasugrel use afforded
ischemic beneﬁt irrespective of stent length in real-world ACS pa-
tients undergoing PCI.CATEGORIES CORONARY: Pharmacology/Pharmacotherapy
KEYWORDS Acute coronary syndromes, Angioplasty, Antiplatelet
therapy
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United StatesBACKGROUND Despite pharmacological advantages, prasugrel may
be preferentially used in patients with higher body-mass index (BMI)
in the real-world due to concerns regarding bleeding. We sought to
examine the frequency of prasugrel use in patients with lower (<30)
and higher (30) BMI, and to compare the MACE rate in these sub-
groups for patients treated with prasugrel versus clopidogrel.
METHODS PROMETHEUS was a retrospective multicenter observa-
tional study comparing clopidogrel and prasugrel use in patients un-
dergoing PCI for acute coronary syndrome. MACE was deﬁned as a
composite of death, myocardial infarction, stroke and unplanned
revascularization at one year. We compared outcomes between clo-
pidogrel and prasugrel treatment stratiﬁed by BMI.
RESULTS Prasugrel was given to 19.0% and 22.0% of patients with
BMI<30 (n¼10678) and BMI30 (n¼9184) respectively. Compared
with clopidogrel, prasugrel treated patients were younger, male, with
less diabetes or prior PCI but greater incidence of smoking at baseline
and a STEMI/NSTEMI presentation. They had a greater incidence of
B2/C type lesions but single vessel and non-signiﬁcantly calciﬁed
disease with a greater likelihood to receive longer stents and stents
>3.0mm in diameter. The overall crude MACE rate for the study
population was 12.1% vs 20.7% with prasugrel compared with clopi-
dogrel, p<0.001. In the BMI<30 group prasugrel was associated with a
signiﬁcantly lower risk for MACE prior to adjustment (12.7% vs. 21.3%,
p<0.001). Analogous event rates in the BMI30 group were 11.5% and
19.9%, respectively (p<0.001). Results remained signiﬁcant for
BMI30 but not BMI<30 without evidence of interaction after
adjustment (p¼0.98) (Figure).
CONCLUSIONS In a real world setting, the use of prasugrel was
similar in patients with BMI < and 30. Compared with clopidogrel,
prasugrel use afforded ischemic beneﬁt irrespective of BMI in real-
world ACS patients undergoing PCI.
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